Capturing circulating tumor cells of hepatocellular carcinoma

Wu, Lijun; Pan, Yida; Pei, Xiaoyu; Chen, Hong H; Nguyen, Samantha; Kashyap, Akshay; Liu, Jie J; Wu, Jian

doi:10.1016/j.canlet.2012.07.024

Cited by 56 publications

(29 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This suggests that there may be a direct link between EMT and the acquirement of CTC properties as well as additional dedifferentiation to having CSC properties. It would thus follow that MSCs contribute to a microenvironment that specifically supports circulating CSCs [41], which are able to metastasize and form new metastatic nodules in distant sites [42]. Besides miR-10b, other microRNAs of note include miR-373 and miR-155.…”

mentioning

confidence: 99%

Involvement of Mesenchymal Stem Cells in Cancer Progression and Metastases

Chang¹,

Schwertschkow²,

Nolta³

et al. 2015

CCDT

Self Cite

View full text Add to dashboard Cite

Mesenchymal stem/stromal cells (MSCs) are known to be the helpers for the healing of tissue damage, often referred to as ambulatory cells. However, MSCs are also recruited by cancer cells to similarly aid in tumor growth and progression. In this review, some of the key steps in cancer progression and metastases are described including the various steps in which MSCs participate and may play important roles. MSCs aid in cancer cells' ability to evade immune attack, while promoting tumor angiogenesis, even being counter-acting against chemotherapeutics and other drugs used to fight various cancers. Furthermore, MSCs participate in many of the crucial steps in invasion and metastasis, including stimulating the epithelial-mesenchymal transition (EMT) and induction of stem-like properties that allow cancer stem cells to increase their survivability through the circulation. These steps are described in detail. Differences between circulating tumor cells (CTCs) and cancer stem cells (CSCs) are discussed, along with descriptions of the formation of a pre-metastatic niche, the role of exosomes from both cancer cells and MSCs in metastasis and tumor reseeding (self-seeding). More and more, MSCs are being proposed as a promising tumor targeting drug-delivery tool. In order to fulfill this promise, further understanding of the precise roles that MSCs play in the process of cancer metastases must be achieved, in attempting to create remedies that will improve the outcome of available therapeutics.

show abstract

mentioning

confidence: 99%

Involvement of Mesenchymal Stem Cells in Cancer Progression and Metastases

Chang¹,

Schwertschkow²,

Nolta³

et al. 2015

CCDT

Self Cite

View full text Add to dashboard Cite

show abstract

“…21 This method has been widely used for various solid carcinomas, including liver, esophageal and breast cancers. 7,17,22 Harvested tumor cells by this technique are active and visible, allowing for identification of CTCs at morphological, immunocytologic, and genetic levels. By the staining of CK5/6, P63 and EBERs, tumor cells were further confirmed in this study.…”

Section: Discussionmentioning

confidence: 99%

The association between circulating tumor cells and Epstein-Barr virus activation in patients with nasopharyngeal carcinoma

Huang

et al. 2017

Cancer Biology & Therapy

View full text Add to dashboard Cite

Background: Circulating tumor cells (CTCs) and microemboli (CTM) are attracting increasing attention in medical biology and clinical practice. However, the clinical relevance of CTCs in nasopharyngeal carcinoma (NPC) has not yet been ascertained, and no study has focused on the influence of Epstein-Barr virus (EBV) status on CTCs in NPC patients. These issues were therefore examined. Methods: Peripheral blood samples were prospectively obtained from 33 NPC patients before treatment. CTCs and CTM were captured using the Isolation by Size of Epithelial Tumor (ISET) method. Immunohistochemistry on CK5/6 (cytokeratin5/6) and P63, as well as in situ hybridization of EBERs (EBV-encoded RNAs) were used to validate the harvested tumor cells. Results: Out of 33 NPC patients, CTCs were detected in 22 cases (66.7%), and CTM were observed in 2 cases (6.1%). CTCs were presented in all stages of NPC patients but had no association with the TNM stages (all P > 0.05). The presence of CTCs appeared to correlate with EBV activation status. Among the total NPC patients, the EBV VCA-IgA levels in CTC-positive cases were higher than that in CTC-negative cases (negative vs. positive: 3.88 vs. 4.86, P D 0.016). A similar result was observed in the patients without distant metastasis (negative vs. positive: 3.76 vs. 4.95, P D 0.009). When the number of CTCs was considered, CTC counts were found to correlate with EBV VCA-IgA (R D 0.382, P D 0.041) and EBV DNA load (R D 0.396, P D 0.033) for all NPC patients as well as NPC patients without distant metastases. Conclusions: These findings strongly suggested detectable CTCs/CTM in all stages of NPC patients and support a positive correlation between CTCs and EBV activation in NPC patients.

show abstract

“…Several membrane‐based microfilters have been developed for size‐based microfluidic capture and isolation of CTCs from peripheral blood samples 57, 58. Hosokawa et al developed a microfluidic device equipped with a nickel microfilter for size‐based selective CTCs capture and isolation ( Figure 2 A) 59.…”

Section: Microfluidics‐based Materials Interface For Ctcs Capturementioning

confidence: 99%

Rational Design of Materials Interface for Efficient Capture of Circulating Tumor Cells

Chandran

Lim

et al. 2015

Advanced Science

View full text Add to dashboard Cite

Originating from primary tumors and penetrating into blood circulation, circulating tumor cells (CTCs) play a vital role in understanding the biology of metastasis and have great potential for early cancer diagnosis, prognosis and personalized therapy. By exploiting the specific biophysical and biochemical properties of CTCs, various material interfaces have been developed for the capture and detection of CTCs from blood. However, due to the extremely low number of CTCs in peripheral blood, there exists a need to improve the efficiency and specificity of the CTC capture and detection. In this regard, a critical review of the numerous reports of advanced platforms for highly efficient and selective capture of CTCs, which have been spurred by recent advances in nanotechnology and microfabrication, is essential. This review gives an overview of unique biophysical and biochemical properties of CTCs, followed by a summary of the key material interfaces recently developed for improved CTC capture and detection, with focus on the use of microfluidics, nanostructured substrates, and miniaturized nuclear magnetic resonance‐based systems. Challenges and future perspectives in the design of material interfaces for capture and detection of CTCs in clinical applications are also discussed.

show abstract

Capturing circulating tumor cells of hepatocellular carcinoma

Cited by 56 publications

References 50 publications

Involvement of Mesenchymal Stem Cells in Cancer Progression and Metastases

Involvement of Mesenchymal Stem Cells in Cancer Progression and Metastases

The association between circulating tumor cells and Epstein-Barr virus activation in patients with nasopharyngeal carcinoma

Rational Design of Materials Interface for Efficient Capture of Circulating Tumor Cells

Contact Info

Product

Resources

About